GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benitec Biopharma Inc (NAS:BNTC) » Definitions » Shiller PE Ratio

Benitec Biopharma (Benitec Biopharma) Shiller PE Ratio : (As of Apr. 29, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Benitec Biopharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Benitec Biopharma Shiller PE Ratio Historical Data

The historical data trend for Benitec Biopharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benitec Biopharma Shiller PE Ratio Chart

Benitec Biopharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Benitec Biopharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Benitec Biopharma's Shiller PE Ratio

For the Biotechnology subindustry, Benitec Biopharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Benitec Biopharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benitec Biopharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Benitec Biopharma's Shiller PE Ratio falls into.



Benitec Biopharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Benitec Biopharma's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Benitec Biopharma's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-2.64/129.4194*129.4194
=-2.640

Current CPI (Dec. 2023) = 129.4194.

Benitec Biopharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201306 -1.553 98.518 -2.040
201312 0.000 98.326 0.000
201406 -2.642 100.560 -3.400
201412 0.000 99.070 0.000
201503 -1.760 99.621 -2.286
201506 -10.403 100.684 -13.372
201509 -235.620 100.392 -303.749
201512 -11.504 99.792 -14.919
201603 -5.088 100.470 -6.554
201606 -8.834 101.688 -11.243
201609 15.559 101.861 19.768
201612 -4.605 101.863 -5.851
201703 -0.368 102.862 -0.463
201706 -2.907 103.349 -3.640
201709 -56.018 104.136 -69.619
201712 -3.325 104.011 -4.137
201803 -3.027 105.290 -3.721
201806 -42.800 106.317 -52.100
201809 0.000 106.507 0.000
201812 9.914 105.998 12.105
201903 0.000 107.251 0.000
201906 0.000 108.070 0.000
201909 -22.780 108.329 -27.215
201912 -34.000 108.420 -40.585
202003 -33.320 108.902 -39.598
202006 -46.580 108.767 -55.424
202009 -41.650 109.815 -49.085
202012 -12.920 109.897 -15.215
202103 -13.940 111.754 -16.143
202106 -8.328 114.631 -9.402
202109 -10.540 115.734 -11.786
202112 -10.030 117.630 -11.035
202203 -6.800 121.301 -7.255
202206 -10.541 125.017 -10.912
202209 -7.980 125.227 -8.247
202212 -3.340 125.222 -3.452
202303 -2.720 127.348 -2.764
202306 -2.832 128.729 -2.847
202309 -2.760 129.860 -2.751
202312 -2.640 129.419 -2.640

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Benitec Biopharma  (NAS:BNTC) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Benitec Biopharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Benitec Biopharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Benitec Biopharma (Benitec Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
3940 Trust Way, Hayward, CA, USA, 94545
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.
Executives
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Megan Boston director, officer: Executive Director LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000
Steven Michael Oliveira 10 percent owner 18 FIELDSTONE COURT, NEW CITY NY 10956
Patrick Soon-shiong 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Edward F Smith director C/O POLYMEDIX, INC., 3701 MARKET STREET, PHILADELPHIA PA 19104
California Capital Equity, Llc 10 percent owner 10182 CULVER BOULEVARD, CULVER CITY CA 90232
Nant Capital, Llc 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Peter Francis director LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000
Jerel A. Banks director, officer: Chief Executive Officer LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000